ABSTRACT
The synthesis of a new series of 1-[ω-(bromophenoxy)alkyl]-uracil derivatives containing in position 3 naphthalen-1-yl-, naphthalen-2-yl-, 1-bromonaphthalen-2-ylmethyl, benzyl, and anthracene 9-methyl fragment was carried out. The antiviral properties of the synthesized compounds were studied against human cytomegalovirus. It was found that the compound that contained a bridge of five methylene groups has a high anti-cytomegalovirus activity in vitro.
Subject(s)
Cytomegalovirus , Uracil , Humans , Uracil/pharmacology , Structure-Activity Relationship , Antiviral Agents/pharmacologyABSTRACT
A new series of 1-[ω-(bromophenoxy)alkyl]-uracil derivatives containing naphthalen-1-yl, naphthalen-2-yl, 1-bromonaphthalen-2-ylmethyl, benzyl, and anthracene-9-ylmethyl fragments in position 3 of uracil residue was synthesized. The antiviral properties of the synthesized compounds against human cytomegalovirus were studied. It was found that the compound containing a bridge consisting of five methylene groups exhibits a high anti-cytomegalovirus activity in vitro.
Subject(s)
Cytomegalovirus , Uracil , Humans , Uracil/pharmacology , Uracil/chemistry , Structure-Activity Relationship , Antiviral Agents/pharmacology , Antiviral Agents/chemistryABSTRACT
A series of uracil derivatives containing a 4-oxoquinazoline fragment bound to the nitrogen atom N3 of the pyrimidine ring by a short methylene bridge was synthesized to search for new antiviral agents. Some compounds in this series are shown to exhibit high inhibitory activity against human cytomegalovirus and the varicella zoster virus in a HEL cell culture.
ABSTRACT
Condylomata acuminata (CA) or anogenital warts are benign proliferative lesions caused by low-risk human papillomaviruses (HPV). Treating CA can be very frustrating for patients and clinicians due to the high recurrence rates. Immunosuppression is associated with larger size of CA that are more frequently resistant to treatment. Surgical approaches tend to be poorly effective in the long-term because of high recurrence rates related to the persistence of HPV-infected cells. In our search to find an agent to treat intraurethral CA with minor or no side effects, we evaluated intraurethral cidofovir in two male patients, who were under immunosuppressing therapy due to organ transplantation and suffered from extensive urethral HPV lesions. Both patients underwent biopsy of the lesions and initial transurethral resection. In our first case, intraurethral cidofovir instillations were started after 2 months due to recurrence after surgical treatment. In our second case, intraurethral cidofovir was administered after surgery because of incomplete resection of extensive lesions. Because of persistent or rapidly recurrent lesions despite intraurethral cidofovir instillations, the first patient needed two additional surgical interventions while the second patient underwent one additional surgical intervention. After surgical intervention, both patients received again adjuvant cidofovir instillations without side effects. Over a period of 56 weeks, both patients received each a total of 28 instillations with cidofovir. Following 3.5 years (patient 1) of the last cidofovir instillation, no recurrences were observed in our first patient. Following 6 months of the last cidofovir instillation (patient 2), two very small recurrent lesions in the most distal part of the urethra were observed in our second patient for which he will receive a cycle of 6 cidofovir instillations in the near future. Intraurethral cidofovir is a safe, easy-to-use, well-tolerated and an effective adjuvant to surgery for extensive intraurethral CA in immunocompromised patients.
Subject(s)
Cidofovir/therapeutic use , Condylomata Acuminata/drug therapy , Condylomata Acuminata/surgery , Immunocompromised Host , Papillomaviridae/drug effects , Papillomavirus Infections/drug therapy , Administration, Topical , Adult , Biopsy , Cetomacrogol/therapeutic use , Condylomata Acuminata/pathology , Humans , Laser Therapy , Male , Middle Aged , Organ Transplantation , Papillomavirus Infections/virology , RecurrenceABSTRACT
Haemophagocytic lymphohistiocytosis (HLH) constitutes a spectrum of immunological disorders characterized by uncontrolled immune activation and key symptoms such as fever, splenomegaly, pancytopenia, haemophagocytosis, hyperferritinaemia and hepatitis. In genetic or primary HLH, hyperactivated CD8+ T cells are the main drivers of pathology. However, in acquired secondary HLH, the role of lymphocytes remains vague. In the present study the involvement of lymphocytes in the pathogenesis of a cytomegalovirus-induced model of secondary HLH was explored. We have previously reported CD8+ T cells to be redundant in this model, and therefore focused on CD4+ helper and regulatory T cells. CD4+ T cells were activated markedly and skewed towards a proinflammatory T helper type 1 transcription profile in mice displaying a severe and complete HLH phenotype. Counter to expectations, regulatory T cells were not reduced in numbers and were, in fact, more activated. Therapeutic strategies targeting CD25high hyperactivated T cells were ineffective to alleviate disease, indicating that T cell hyperactivation is not a pathogenic factor in cytomegalovirus-induced murine HLH. Moreover, even though T cells were essential in controlling viral proliferation, CD4+ T cells, in addition to CD8+ T cells, were dispensable in the development of the HLH-like syndrome. In fact, no T or B cells were required for induction and propagation of HLH disease, as evidenced by the occurrence of cytomegalovirus-associated HLH in severe combined immunodeficient (SCID) mice. These data suggest that lymphocyte-independent mechanisms can underlie virus-associated secondary HLH, accentuating a clear distinction with primary HLH.
Subject(s)
CD4-Positive T-Lymphocytes/immunology , Herpesviridae Infections/immunology , Lymphohistiocytosis, Hemophagocytic/immunology , Lymphohistiocytosis, Hemophagocytic/pathology , T-Lymphocytes, Regulatory/immunology , Animals , Herpesviridae Infections/complications , Interferon-gamma/genetics , Lymphocyte Activation , Lymphocyte Depletion , Lymphohistiocytosis, Hemophagocytic/virology , Mice , Mice, Inbred BALB C , Mice, Knockout , Muromegalovirus , Th1 Cells/immunologyABSTRACT
Emergence of drug-resistance to all FDA-approved antiherpesvirus agents is an increasing concern in immunocompromised patients. Herpesvirus DNA polymerase (DNApol) is currently the target of nucleos(t)ide analogue-based therapy. Mutations in DNApol that confer resistance arose in immunocompromised patients infected with herpes simplex virus 1 (HSV-1) and human cytomegalovirus (HCMV), and to lesser extent in herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV) and human herpesvirus 6 (HHV-6). In this review, we present distinct drug-resistant mutational profiles of herpesvirus DNApol. The impact of specific DNApol amino acid changes on drug-resistance is discussed. The pattern of genetic variability related to drug-resistance differs among the herpesviruses. Two mutational profiles appeared: one favoring amino acid changes in the Palm and Finger domains of DNApol (in α-herpesviruses HSV-1, HSV-2 and VZV), and another with mutations preferentially in the 3'-5' exonuclease domain (in ß-herpesvirus HCMV and HHV-6). The mutational profile was also related to the class of compound to which drug-resistance emerged.
Subject(s)
Amino Acid Substitution , DNA Polymerase I/genetics , DNA Polymerase I/metabolism , DNA Polymerase beta/genetics , DNA Polymerase beta/metabolism , DNA-Directed DNA Polymerase/genetics , DNA-Directed DNA Polymerase/metabolism , Drug Resistance, Viral , Exodeoxyribonucleases/genetics , Exodeoxyribonucleases/metabolism , Viral Proteins/genetics , Viral Proteins/metabolism , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Catalysis , Conserved Sequence , DNA Polymerase I/chemistry , DNA Polymerase beta/chemistry , DNA-Directed DNA Polymerase/chemistry , Enzyme Activation , Evolution, Molecular , Exodeoxyribonucleases/chemistry , Herpesviridae/classification , Herpesviridae/drug effects , Herpesviridae/genetics , Humans , Mutation , Phenotype , Protein Interaction Domains and Motifs , Protein Multimerization , Structure-Activity Relationship , Viral Proteins/chemistryABSTRACT
A series of novel uracil derivatives, bearing N-(4-phenoxyphenyl)acetamide moiety at N3 of a pyrimidine ring, has been synthesized. Their antiviral activity has been evaluated. It has been found that the novel compounds possess high inhibitory activity against replication of human cytomegalovirus (AD-169 and Davis strains) in HEL cell cultures. In addition, some of the derivatives proved to be inhibitory against varicella zoster virus.
ABSTRACT
Acyclic nucleoside phosphonates (ANPs) are well-known for their antiviral properties, three of them being approved for the treatment of human immunodeficiency virus infection (tenofovir), chronic hepatitis B (tenofovir and adefovir) or human cytomegalovirus retinitis (cidofovir). In addition, cidofovir is mostly used off-label for the treatment of infections caused by several DNA viruses other than cytomegalovirus, including papilloma- and polyomaviruses, which do not encode their own DNA polymerases. There is considerable interest in understanding why cidofovir is effective against these small DNA tumor viruses. Considering that papilloma- and polyomaviruses cause diseases associated either with productive infection (characterized by high production of infectious virus) or transformation (where only a limited number of viral proteins are expressed without synthesis of viral particles), it can be envisaged that cidofovir may act as antiviral and/or antiproliferative agent. The aim of this review is to discuss the advances in recent years in understanding the mode of action of ANPs as antiproliferative agents, given the fact that current data suggest that their use can be extended to the treatment of non-viral related malignancies.
Subject(s)
Antineoplastic Agents/pharmacology , Antiviral Agents/pharmacology , Cytosine/analogs & derivatives , Neoplasms/drug therapy , Organophosphonates/pharmacology , Papillomaviridae/drug effects , Polyomavirus/drug effects , Animals , Antineoplastic Agents/therapeutic use , Antiviral Agents/therapeutic use , Cell Line, Tumor , Cell Proliferation/drug effects , Cidofovir , Cytosine/pharmacology , Cytosine/therapeutic use , Humans , Organophosphonates/therapeutic use , Papillomaviridae/genetics , Papillomaviridae/physiology , Papillomavirus Infections/drug therapy , Papillomavirus Infections/virology , Polyomavirus/genetics , Polyomavirus/physiology , Polyomavirus Infections/drug therapy , Polyomavirus Infections/virology , Tumor Suppressor Protein p53ABSTRACT
In immunocompromised patient, parapoxvirus infection can be extensively necrotic and recurrent evolution. We describe a case of Orf nodule in a liver transplanted woman. We will consider the therapeutic options in case of infections by parapox in immunosuppressive patients, as described in the medical literature. In our specific case, local application of cidofovir (concentration of 1 %) together with local antiseptic solution, povidone iodine, led to complete remission of the lesion without any sign of toxicity. Finally, we will consider the therapeutic use of local cidofovir.
Subject(s)
Ecthyma, Contagious/drug therapy , Immunocompromised Host , Orf virus , Transplant Recipients , Adult , Antiviral Agents/therapeutic use , Cidofovir , Cytosine/analogs & derivatives , Cytosine/therapeutic use , Female , Humans , Liver Transplantation , Opportunistic Infections/drug therapy , Organophosphonates/therapeutic useABSTRACT
Varicella-zoster virus (VZV) causes two distinct diseases, varicella (chickenpox) and shingles (herpes zoster). Chickenpox occurs subsequent to primary infection, while herpes zoster (usually associated with aging and immunosuppression) appears as a consequence of reactivation of latent virus. The major complication of shingles is postherpetic neuralgia. Vaccination strategies to prevent varicella or shingles and the current status of antivirals against VZV will be discussed in this chapter. Varivax®, a live-attenuated vaccine, is available for pediatric varicella. Zostavax® is used to boost VZV-specific cell-mediated immunity in adults older than 50 years, which results in a decrease in the burden of herpes zoster and pain related to postherpetic neuralgia. Regardless of the availability of a vaccine, new antiviral agents are necessary for treatment of VZV infections. Current drugs approved for therapy of VZV infections include nucleoside analogues that target the viral DNA polymerase and depend on the viral thymidine kinase for their activation. Novel anti-VZV drugs have recently been evaluated in clinical trials, including the bicyclic nucleoside analogue FV-100, the helicase-primase inhibitor ASP2151, and valomaciclovir (prodrug of the acyclic guanosine derivative H2G). Different candidate VZV drugs have been described in recent years. New anti-VZV drugs should be as safe as and more effective than current gold standards for the treatment of VZV, that is, acyclovir and its prodrug valacyclovir.
Subject(s)
Antiviral Agents/therapeutic use , Chickenpox/drug therapy , Chickenpox/prevention & control , Herpes Zoster/drug therapy , Herpes Zoster/prevention & control , Herpesvirus 3, Human/drug effects , Animals , Antiviral Agents/pharmacology , Chickenpox/virology , Drugs, Investigational/pharmacology , Drugs, Investigational/therapeutic use , Herpes Zoster/virology , Humans , Vaccination/adverse effectsABSTRACT
A novel nucleoside analogue, 1-[(2S,4S-2-(hydroxymethyl)-1,3-dioxolan-4-yl]5-vinylpyrimidine-2,4(1H,3H)-dione, or HDVD, was evaluated against a wide variety of herpesviruses and was found to be a highly selective inhibitor of replication of the gammaherpesviruses Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV). HDVD had also a pronounced inhibitory activity against murine herpesvirus 68 (MHV-68) and herpes simplex virus 1 (HSV-1). In contrast, replication of herpesvirus saimiri (HVS), HSV-2, and varicella-zoster virus (VZV) was weakly inhibited by the compound, and no antiviral activity was determined against human cytomegalovirus (HCMV) and rhesus rhadinovirus (RRV). The HDVD-resistant virus phenotype contained point mutations in the viral thymidine kinase (TK) of HSV-1, MHV-68, and HVS isolates. These mutations conferred cross-resistance to other TK-dependent drugs, with the exception of an MHV-68 mutant (E358D) that exhibited resistance only to HDVD. HSV-1 and HVS TK-mutants isolated under selective pressure with bromovinyldeoxyuridine (BVDU) also showed reduced sensitivity to HDVD. Oral treatment with HDVD and BVDU was assessed in an intranasal model of MHV-68 infection in BALB/c mice. In contrast to BVDU treatment, HDVD-treated animals showed a reduction in viral DNA loads and diminished viral gene expression during acute viral replication in the lungs in comparison to levels in untreated controls. The valyl ester prodrug of HDVD (USS-02-71-44) suppressed the latent infection in the spleen to a greater extent than HDVD. In the present study, HDVD emerged as a highly potent antiviral with a unique spectrum of activity against herpesviruses, in particular, gammaherpesviruses, and may be of interest in the treatment of virus-associated diseases.
Subject(s)
Antiviral Agents/pharmacology , Gammaherpesvirinae/drug effects , Nucleosides/pharmacology , Pyrimidine Nucleosides/pharmacology , Pyrimidines/pharmacology , Virus Replication/drug effects , Animals , Antiviral Agents/metabolism , Aotidae , DNA Primers/genetics , Fibroblasts , Gammaherpesvirinae/genetics , Humans , Macaca mulatta , Mice , Mice, Inbred BALB C , Molecular Structure , Mutation/genetics , NIH 3T3 Cells , Nucleosides/chemistry , Nucleosides/metabolism , Pyrimidine Nucleosides/metabolism , Pyrimidines/chemistry , Pyrimidines/metabolism , Real-Time Polymerase Chain Reaction , Rhadinovirus/drug effects , Species Specificity , Statistics, Nonparametric , Thymidine Kinase/geneticsABSTRACT
The SV40 large tumor antigen (L-Tag) is involved in the replication and cell transformation processes that take place during the polyomavirus life cycle. The ability of the L-Tag to interact with and to inactivate the tumor suppressor proteins p53 and pRb, makes this polyfunctional protein an interesting target in the search for compounds with antiviral and/or antiproliferative activities designed for the management of polyomavirus-associated diseases. The severe diseases caused by polyomaviruses, mainly in immunocompromised hosts, and the absence of licensed treatments, make the discovery of new antipolyomavirus drugs urgent. Parallels can be made between the SV40 L-Tag and the human papillomavirus (HPV) oncoproteins (E6 and E7) as they are also able to deregulate the cell cycle in order to promote cell transformation and its maintenance. In this review, a presentation of the SV40 L-Tag characteristics, regarding viral replication and cellular transformation, will show how similar these two processes are between the polyoma- and papillomavirus families. Insights at the molecular level will highlight similarities in the binding of polyoma- and papillomavirus replicative helicases to the viral DNA and in their disruptions of the p53 and pRb tumor suppressor proteins.
Subject(s)
Antigens, Polyomavirus Transforming/metabolism , Cell Transformation, Viral , Polyomavirus/physiology , Virus Replication , Animals , Humans , Oncogene Proteins/metabolism , Papillomaviridae/pathogenicity , Papillomaviridae/physiology , Polyomavirus/pathogenicity , Virulence Factors/metabolismABSTRACT
Varicella zoster virus (VZV) is usually associated with mild to moderate illness in immunocompetent patients. However, older age and immune deficiency are the most important risk factors linked with virus reactivation and severe complications. Treatment of VZV infections is based on nucleoside analogues, such as acyclovir (ACV) and its valyl prodrug valacyclovir, penciclovir (PCV) as its prodrug famciclovir, and bromovinyldeoxyuridine (BVDU; brivudin) in some areas. The use of the pyrophosphate analogue foscarnet (PFA) is restricted to ACV-resistant (ACV(r)) VZV infections. Since antiviral drug resistance is an emerging problem, we attempt to describe the contributions of specific mutations in the viral thymidine kinase (TK) gene identified following selection with ACV, BVDU and its derivative BVaraU (sorivudine), and the bicyclic pyrimidine nucleoside analogues (BCNAs), a new class of potent and specific anti-VZV agents. The string of 6 Cs at nucleotides 493 to 498 of the VZV TK gene appeared to function as a hot spot for nucleotide insertions or deletions. Novel amino acid substitutions (G24R and T86A) in VZV TK were also linked to drug resistance. Six mutations were identified in the "palm domain" of VZV DNA polymerase in viruses selected for resistance to PFA, PCV, and the 2-phophonylmethoxyethyl (PME) purine derivatives. The investigation of the contributions of specific mutations in VZV TK or DNA polymerase to antiviral drug resistance and their impacts on the structures of the viral proteins indicated specific patterns of cross-resistance and highlighted important differences, not only between distinct classes of antivirals, but also between ACV and PCV.
Subject(s)
Antiviral Agents/pharmacology , DNA-Directed DNA Polymerase/genetics , Drug Resistance, Viral , Herpesvirus 3, Human/enzymology , Mutation/drug effects , Nucleosides/pharmacology , Thymidine Kinase/genetics , Viral Proteins/genetics , Amino Acid Sequence , Cell Line , DNA-Directed DNA Polymerase/chemistry , DNA-Directed DNA Polymerase/metabolism , Drug Evaluation, Preclinical , Genotype , Herpesviridae Infections/virology , Herpesvirus 3, Human/chemistry , Herpesvirus 3, Human/drug effects , Herpesvirus 3, Human/genetics , Humans , Models, Molecular , Molecular Sequence Data , Phenotype , Sequence Alignment , Thymidine Kinase/chemistry , Thymidine Kinase/metabolism , Viral Proteins/metabolismABSTRACT
BK virus (BKV), a virus belonging to the polyomavirus family, is a circular double-stranded DNA virus that causes nephropathies in immunocompromised patients after kidney or bone marrow transplantation. The occurrence of polyomavirus-associated nephropathy in kidney transplant patients may trigger graft loss, and guidelines for the management of BKV infection have not yet been clearly established. Treatment of BKV nephropathy with cidofovir (CDV) {(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (HPMPC)}, an acyclic phosphonate analogue of dCMP with a broad antiviral activity against DNA virus infections, has been proposed. The benefit of this small-molecule-based treatment has been evaluated only with a limited number of cases. In this study, we report the evaluation of three different classes of acyclic nucleoside phosphonates for their activities against BKV replication in two different primary renal cells: renal proximal tubular epithelial cells (RPTECs) and human renal cortical epithelial (HRCE) cells. The data indicate that besides HPMPC and its cyclic form, (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC), cyclic HPMP (cHPMP)-5-azaC, hexadecyloxyethyl (HDE)-cHPMP-5-azaC, and 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG) are the most selective inhibitors of BKV replication. On the contrary, leflunomide, which has also been proposed for the management of BKV-associated diseases, is not able to inhibit BKV replication at nontoxic concentrations.
Subject(s)
BK Virus/drug effects , Nucleosides/pharmacology , Organophosphonates/pharmacology , Cell Line , Cell Proliferation/drug effects , Cidofovir , Cytarabine/pharmacology , Cytosine/analogs & derivatives , Cytosine/pharmacology , Humans , Isoxazoles/pharmacology , Kidney/cytology , Leflunomide , Polymerase Chain Reaction , Vidarabine/pharmacologyABSTRACT
The organotypic epithelial raft cultures, originally developed to study keratinocytes differentiation, represent a novel approach to the study of viruses able to infect epithelial cells. Organotypic epithelial raft cultures accurately reproduce the process of epithelial differentiation in vitro and can be prepared from normal keratinocytes, explanted epithelial tissue, or established cell lines. This culture system permits cells to proliferate and fully differentiate at the air-liquid interface on a dermal-equivalent support. Normal primary human keratinocytes (PHKs) stratify and fully differentiate in a manner similar to the normal squamous epithelial tissues, while transformed cell lines exhibit dysplastic morphologies similar to the (pre)neoplastic lesions seen in vivo. This three-dimensional (3D) culture system provides an essential tool for investigations of virus growth, virus-host cell interactions, for the genetic analysis of viral proteins and regulatory sequences, and for the evaluation of antiviral agents. The 3D epithelial cultures have proven a breakthrough in the research on papillomaviruses, since their life cycle is strictly linked to the differentiation of the host epithelium. In the last years, several reports have shown the usefulness of the 3D epithelial cultures for the study of other viruses that target at least during a part of their life cycles epithelial cells. The 3D epithelial cultures allow the analysis of virus-host cell interactions in stratified epithelia that more closely resemble the in vivo situation. In this review we describe the advances on research on 3D epithelial cultures for the study of virus growth and pathogenesis of different families of viruses, including papilloma-, herpes-, pox-, adeno-, and parvoviruses.
Subject(s)
Antiviral Agents/pharmacology , Epithelial Cells/virology , Viruses/drug effects , Viruses/pathogenicity , Cell Culture Techniques , Cell Differentiation , Cells, Cultured , Humans , Organ Culture Techniques/methodsABSTRACT
OBJECTIVE: Randomized controlled trial evaluating a topical treatment for cervical intraepithelial neoplasia 2 and 3 (CIN 2+) using cidofovir. METHODS: Fifty-three women with a biopsy-proven CIN 2+ were randomly assigned, 6 weeks before their planned conisation, either 3 applications of 3 ml 2% cidofovir in Intrasite gel in a cervical cap or a placebo (the same volume of Intrasite alone). A cervical sample for high-risk types of human papillomaviruses (HPV) (Hybrid Capture 2 or HC2) was taken before treatment and before conisation. The cone was submitted for pathological examination, and subsequently, along with the initial biopsy, to in situ hybridization (ISH) for high-risk HPV. RESULTS: Forty-eight patients were treated and followed according to the protocol, (23 cidofovir, and 25 placebo). Fourteen of the 23 cones were free of any CIN (60.8%) in the cidofovir group. Only 5 of 25 cones were free of any CIN (20%) in the placebo group (p<0.01). The difference remained significant in the ITT group (p<0.05). In the per-protocol and ITT populations, we observed more frequent viral clearance in the cidofovir group, but the difference was significant only when evaluated by ISH and not by HC2. No systemic toxicity was observed. Cervico-vaginal side effects of cidofovir were limited, and not statistically different from placebo. CONCLUSION: The medical topical treatment with cidofovir, at this point, cannot replace conisation, but it is a promising candidate for topical chemotherapy of CIN 2+ lesions; a larger prospective randomized study is needed to confirm our results.
Subject(s)
Antineoplastic Agents/administration & dosage , Cytosine/analogs & derivatives , Organophosphonates/administration & dosage , Uterine Cervical Dysplasia/drug therapy , Uterine Cervical Neoplasms/drug therapy , Administration, Topical , Adult , Antineoplastic Agents/adverse effects , Cidofovir , Combined Modality Therapy , Conization , Contraceptive Devices, Female , Cytosine/administration & dosage , Cytosine/adverse effects , Double-Blind Method , Female , Gels/administration & dosage , Humans , Organophosphonates/adverse effects , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Placebos , Prospective Studies , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/surgery , Uterine Cervical Neoplasms/virology , Uterine Cervical Dysplasia/pathology , Uterine Cervical Dysplasia/surgery , Uterine Cervical Dysplasia/virologyABSTRACT
The target phosphoramidates 5a-e were prepared in one step from 3-hydroxypropyl derivatives 3a-e of nonsteroidal anti-inflammatory drugs (fenoprofen, ketoprofen, ibuprofen, indomethacin, diclofenac). The products 3a-e and 5a-e were evaluated for their cytostatic and antiviral activity against malignant tumour cell lines and normal human fibroblasts (WI 38). All phosphoramidate derivatives 5a-e possess significantly greater inhibitory activities than the corresponding 3-hydroxypropyl derivatives 3a-e, whereby compound 5a showed the most potent inhibitory activities against cervical, pancreatic and colon carcinoma cell lines (IC(50)=5-7 microM).
Subject(s)
Amides/chemical synthesis , Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis , Antineoplastic Agents/chemical synthesis , Phosphoric Acids/chemical synthesis , Amides/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antineoplastic Agents/pharmacology , Antiviral Agents , Cell Line , Cell Line, Tumor , Cytostatic Agents/chemical synthesis , Fibroblasts , Humans , Inhibitory Concentration 50 , Phosphoric Acids/pharmacology , Structure-Activity RelationshipABSTRACT
The novel urea primaquine derivatives 3a-i were prepared by aminolysis of benzotriazolide 2 with the corresponding amine in the presence or absence of triethylamine. Compound 2 was prepared by acylation of primaquine with 1-benzotriazole carboxylic acid chloride. Among all compounds evaluated, the pyridine derivative 3h exhibited the best cytostatic activities against colon carcinoma, human T-lymphocyte and murine leukemia. However, this compound showed also rather marked cytotoxicity towards human normal fibroblasts. The highest selectivity in the inhibitory effects on human malignant tumor cell lines vs. normal fibroblasts was found for ureas 3c, 3d and 3g. Results of broad antiviral evaluation showed that pyridine and phenethyl derivatives of urea 3h and 3g exhibited some selective inhibition against cytomegalovirus.
Subject(s)
Antiviral Agents/chemical synthesis , Antiviral Agents/pharmacology , Primaquine/chemistry , Urea/analogs & derivatives , Urea/pharmacology , Animals , Chlorocebus aethiops , HeLa Cells , Humans , Magnetic Resonance Spectroscopy , Microbial Sensitivity Tests , Spectroscopy, Fourier Transform Infrared , Tandem Mass Spectrometry , Urea/chemical synthesisABSTRACT
Poxviruses include several pathogens responsible for diseases recognized as important for human health, such as smallpox, monkeypox, orf and molluscum contagiosum. Smallpox, whose etiological agent is Variola virus, is a highly contagious disease which was eradicated last century. Today, the potential use of Variola virus in bioterrorism is real. Hence, efforts have been intensified for the selection of novel anti-poxvirus compounds. The increased understanding of the poxviral replication, the establishment of threedimensional cell cultures, as well as the validation of several animal models, have led to the discovery and the development of new and promising classes of compounds active against poxviruses. Cidofovir, an acyclic cytosine phosphonate analogue and hexadecylpropanediol-cidofovir (CMX001), one of its prodrug orally bioavailable, inhibit poxvirus replication in vitro, ex vivo and in vivo by targeting the viral DNA polymerase. Another compound, ST-246, inhibits a crucial step of the orthopoxvirus morphogenesis. Its antiviral activity has been demonstrated in several animal models, and its safety has been confirmed in healthy human volunteers following a phase I clinical trial. Recent developments made in vitro, ex vivo, in vivo and in humans, in terms of antiviral treatments available of poxvirus infections, are discussed in this review.
ABSTRACT
A hematopoietic stem cell transplant recipient developed a mucosal herpes simplex virus-1 (HSV-1) infection while under acyclovir (ACV) treatment (HSV was later shown to be resistant to ACV). Concomitantly, the patient presented a hemorrhagic cystitis (HC) due to polyomavirus BK, for which intravenous cidofovir (CDV) was prescribed. The patient benefited from the broad-spectrum anti-DNA virus activity of CDV, and not only the HC resolved without signs of nephrotoxicity but also the HSV-1 lesions disappeared. This is the first report describing the effect of CDV on 2 simultaneous and unrelated DNA viral infections in an immunosuppressed transplant recipient. In addition, we describe here that this HSV-1 isolate possesses a unique phenotype and genotype.